April 2009
Volume 50, Issue 13
Free
ARVO Annual Meeting Abstract  |   April 2009
Intravitreal Ranibizumab and Low Fluence Photodynamic Therapy to Treat Choroidal Neovascularization Due to Age-Related Macular Degeneration
Author Affiliations & Notes
  • G. Besozzi
    Ophthalmology, University of Bari, Bari, Italy
  • F. Boscia
    Ophthalmology, University of Bari, Bari, Italy
  • L. Sborgia
    Ophthalmology, University of Bari, Bari, Italy
  • C. Furino
    Ophthalmology, University of Bari, Bari, Italy
  • N. Cardascia
    Ophthalmology, University of Bari, Bari, Italy
  • R. Dammacco
    Ophthalmology, University of Bari, Bari, Italy
  • G. Sborgia
    Ophthalmology, University of Bari, Bari, Italy
  • A. Ferrara
    Ophthalmology, University of Bari, Bari, Italy
  • C. Sborgia
    Ophthalmology, University of Bari, Bari, Italy
  • Footnotes
    Commercial Relationships  G. Besozzi, None; F. Boscia, None; L. Sborgia, None; C. Furino, None; N. Cardascia, None; R. Dammacco, None; G. Sborgia, None; A. Ferrara, None; C. Sborgia, None.
  • Footnotes
    Support  None.
Investigative Ophthalmology & Visual Science April 2009, Vol.50, 5223. doi:https://doi.org/
  • Views
  • Share
  • Tools
    • Alerts
      ×
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      G. Besozzi, F. Boscia, L. Sborgia, C. Furino, N. Cardascia, R. Dammacco, G. Sborgia, A. Ferrara, C. Sborgia; Intravitreal Ranibizumab and Low Fluence Photodynamic Therapy to Treat Choroidal Neovascularization Due to Age-Related Macular Degeneration. Invest. Ophthalmol. Vis. Sci. 2009;50(13):5223. doi: https://doi.org/.

      Download citation file:


      © ARVO (1962-2015); The Authors (2016-present)

      ×
  • Supplements
Abstract

Purpose: : To evaluate efficacy and safety of intravitreal ranibizumab (IVR) and low fluence photodynamic therapy (LFPDT) protocol to treat choroideal neovascularization due to age-related macular degeneration (AMD-CNV)

Methods: : twenty-three eyes with AMD-CNV (12 naïve and 11 already treated with standard PDT) underwent combined treatment with 0.03 mg IVR (1/month for 3 months) and LFPDT (parameters reduced to 25mJ/cm2, 300mW/cm2, with standard dose of verteporfin and timing) after 5-14 days. Best corrected visual acuity (BCVA) was measured using ETDRS charts; biomicroscopy, fluorescein angiography (FA), and optical coherence tomography (OCT) were performed, in order to evaluate functional and anatomical outcomes

Results: : Mean follow-up was 8.6±2.2 months (range: 5-15). BCVA was improved in all patients and also in subgroups analysis (p>0.05). No patient experienced severe visual loss. No patient showed FA leakage. OCT demonstrated neuroretinal detachement resolution in 20/23 (87%) ad RPE detachment resolution in 9/15 (60%). Three eyes (13%) had IVR+LFPDT single retreatment. No complication were observed.

Conclusions: : combined IVR+LFPDT therapy is safe and effective in AMD-CNV, improving visual acuity and anatomical conditions. Further controlled study is warranted to demonstrate the long term efficacy and safety of this treatment option.

Keywords: age-related macular degeneration • choroid: neovascularization • injection 
×
×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×